Pembrolizumab plus Chemotherapie als Erstlinientherapie beim fortgeschrittenen Ösophaguskarzinom (KEYNOTE-590)

4区医学 Q4 Medicine

Onkologe Pub Date : 2022-03-24 DOI:10.1007/s00761-022-01150-7

M. Hartmann, T. Zander, H. Alakus

引用次数: 0

查看原文本刊更多论文

似乎没有关系

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Onkologe 医学-肿瘤学

CiteScore

0.40

自引率

0.00%

发文量

101

审稿时长

4-8 weeks

期刊介绍： Der Onkologe deals with relevant issues concerning the diagnosis and therapy of oncological diseases. Special emphasis is placed on oncology’s interfaces with the fields of internal medicine, radiology and surgery. This interdisciplinary journal addresses the needs of researchers and doctors working in the field of oncology. The core of each issue consists of comprehensive reviews on a specific topical issue. Here the focus is on providing evidenced based information on diagnostics and therapy relevant for daily practice. After the topics are selected by an independent editorial board, established experts prepare the articles for each issue. Contributions under the rubric ''Continuing Medical Education'' present the verified results of scientific research and their integration into daily practice.